Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
==== Anionic: sulfate, sulfonate, and phosphate, carboxylate derivatives ==== Anionic surfactants contain anionic functional groups at their head, such as sulfate, sulfonate, phosphate, and carboxylates. Prominent alkyl sulfates include ammonium lauryl sulfate, sodium lauryl sulfate (sodium dodecyl sulfate, SLS, or SDS), and the related alkyl-ether sulfates sodium laureth sulfate (sodium lauryl ether sulfate or SLES), and sodium myreth sulfate.
Sinners (Original Motion Picture Soundtrack) won Outstanding Original Score for TV/Film and Outstanding Soundtrack/Compilation Album. On the same day, the Brit Awards 2026 were held. Olivia Dean won British Album of the Year for The Art of Loving, British Artist of the Year and Best Pop Act. Sault won Best R&B Act.
== Design == Adam Foster, Minerva's designer, is critical of Valve's design of Half-Life 2 maps. His belief is that game developers focus on creating gameplay friendly environments that do not work in an architectural way, "a series of unconnected boxes" says Foster, Minerva's environments are built as actual environments (with correctly proportioned structures and areas) with gameplay worked in later. This creates a more open design, in which players may, in places, navigate in multiple ways. Later locations can be seen in earlier stages of the game (along corridors or through windows for example). Map design is the mod's hallmark. While all levels are constructed primarily using Valve's resources, with few new models or textures, Foster follows his own design ideals – that of compact, well designed maps. Although the levels seem huge, as play unfolds, they are in fact very small - wrapping around to use the least space possible. This creates a sense of realism. As pointed out by Planet Half-Life: "Instead of relying on horizontally-sprawling, immense maps that stress the engine's area-capabilities to its max, Minerva maps are incredibly small. This is because of Foster's ground-breaking idea to utilize every possible area to its maximum potential, and instead of expanding horizontally, he expands vertically." As a result, Minerva maps have a much shorter load time than maps in the original game. Foster creates the maps in layers.
Anise tea, made from either the seeds or the leaves Asiatic penny-wort leaf, in South Asia and Southeast Asia Artichoke tea Commiphora gileadensis tea, in the Hijaz region of western Arabia. Bael fruit tea Barley tea, East Asian drink with roasted barley Bee balm Boldo, used in South America Burdock; the seeds, leaves, and roots have been used Butterfly pea flower tea (from Clitoria ternatea), also called "Blue tea" since it produces a blue infusion Caraway, tea made from the seeds Catnip, tea used as a relaxant, sedative, and to calm Chamomile, both Matricaria chamomilla and Chamaemelum nobile can be used Che dang, bitter tea made from Ilex causue leaves Chinese knotweed tea Chrysanthemum tea, made from dried flowers Cinnamon tea Clover tea, made from the blossoms Cerasse, bitter Jamaican herb Citrus peel, including bergamot, lemon and orange peel Dandelion coffee, which does not contain caffeine despite the name Dill tea Dried lime tea, made from dried limes common in western Asia Echinacea tea Elderberry European mistletoe (Viscum album), (steep in cold water for 2–6 hours) Essiac tea, blended herbal tea Fennel Gentian Ginger tea, made from the ginger root, can be made into herbal tea, known in the Philippines as salabat Ginkgo biloba Ginseng tea, a common tea in China and Korea, commonly used as a stimulant and as a caffeine substitute Goji berry tea Hawthorn Hibiscus tea (often blended with rose hip), a common tea in the Middle East or Asia Honeybush, similar to rooibos and grows in a nearby area of South Africa, but tastes slightly sweeter.
Sources: en.wikipedia.org
=== Higher education === During his 2022 gubernatorial campaign, Moore called a plan to cancel up to $20,000 in federal student loan debt a "good first step" and said he would push the Biden administration to forgive more federal student debt if elected governor. In June 2023, Moore opposed the U.S. Supreme Court's ruling in Students for Fair Admissions v. Harvard, which held that race-based affirmative action in college admissions violated the Equal Protection Clause, calling it a "misguided ruling". In April 2024, Moore signed into law a bill banning legacy admissions at Maryland colleges and universities.
=== Wound occlusion === Many animals are able to block off the area around an injury rapidly, by coagulating their blood or body fluid. Invertebrates with hydrostatic skeletons (moving by peristalsis) are unable to move without internal fluid under pressure, while those with an open circulation (body fluid not confined to blood vessels) quickly die from loss of body fluid. In addition, open wounds allow bacteria to enter the body. The invertebrate coagulation system is comparable with the innate immune system (the simpler of two systems of protection against infection) of vertebrates.
Panago (originally Panagopoulos) is a privately owned quick service pizza chain with 174 franchised locations in Canada, 151 of which are in British Columbia and Alberta. It is headquartered in Abbotsford, British Columbia, where in 1986 the first three stores opened. In recent years it has attempted to make its food healthier as provincial healthier eating guidelines became more strict. Offerings include multigrain crusts, salads, 33 pizza toppings, and other menu items that have no trans fat, MSG, artificial flavours or artificial colours.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.